JGIA
TEVA icon

Jackson Grant Investment Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Jackson Grant Investment Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-122
Closed -$2.04K – 416
2025
Q2 		$2.04K Hold
122
– – ﹤0.01% 365
2025
Q1 		$1.88K Hold
122
– – ﹤0.01% 363
2024
Q4 		$2.69K Hold
122
– – ﹤0.01% 360
2024
Q3 		$2.2K Hold
122
– – ﹤0.01% 374
2024
Q2 		$1.98K Hold
122
– – ﹤0.01% 372
2024
Q1 		$1.72K Hold
122
– – ﹤0.01% 368
2023
Q4 		$1.27K Hold
122
– – ﹤0.01% 376
2023
Q3 		$1.24K Hold
122
– – ﹤0.01% 376
2023
Q2 		$919 Hold
122
– – ﹤0.01% 409
2023
Q1 		$1.08K Hold
122
– – ﹤0.01% 440
2022
Q4 		$1.11K Hold
122
– – ﹤0.01% 314
2022
Q3 		$1K Hold
122
– – ﹤0.01% 345
2022
Q2 		$1K Buy
+122
New +$1.06K ﹤0.01% 352
2016
Q1 		– Sell
-200
Closed -$13K – 196
2015
Q4 		$13K Buy
+200
New +$12.4K 0.01% 159

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Jackson Grant Investment Advisers's TEVA Position: Q3 2025 in Review

Jackson Grant Investment Advisers sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 122 shares — an estimated $2.04K sold.

Jackson Grant Investment Advisers first reported a position in TEVA in Q4 2015 and held it in 14 quarters. The position peaked at $13K in Q4 2015. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Jackson Grant Investment Advisers reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Jackson Grant Investment Advisers sold 122 Teva Pharmaceuticals shares in Q3 2025, an estimated $2.04K.
  • Jackson Grant Investment Advisers first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 14 quarters.
  • Jackson Grant Investment Advisers's Teva Pharmaceuticals position peaked at $13K in Q4 2015.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Jackson Grant Investment Advisers's 13F filing for Q3 2025, filed 10 Nov 2025.